Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 28Paclitaxel 19Radiotherapy 17Fluorouracil 13Drug Therapy 12camrelizumab 10toripalimab 8Carboplatin 8Radiation 7Capecitabine 7Radiotherapy, Intensity-Modulated 6sintilimab 5S 1 (combination) 5Esophagectomy 5tislelizumab 4nimotuzumab 4apatinib 4anlotinib 4Irinotecan 4Cetuximab 4Afatinib 4pembrolizumab 3durvalumab 3Vinorelbine 3Positron Emission Tomography Computed Tomography 3Oxaliplatin 3Nivolumab 3Immune Checkpoint Inhibitors 3Docetaxel 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Esophageal Squamous Cell Carcinoma × sinoporphyrin sodium × Clear all
NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Unknown
54 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡